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Summary 
Transforming growth factor B (TGF-~), a multifunctional cytokine, is an indirect mitogen for 
human fibroblasts through platelet-derived  growth factor (PDGF), particularly the A ligand-c~ 
receptor arm of that system. TGF-~ effects on PDGF ot receptor expression were studied in vitro 
using ligand binding techniques in three human dermal fibroblast  strains:  newborn foreskin, 
adult skin, and scleroderma (systemic sclerosis, SSc). Each cell strain  responded differently to 
TGF-~. In newborn foreskin fibroblasts, PDGF c~ receptor number decreased in a dose-dependent 
manner after exposure to low concentrations of TGF-B (0.1-1 ng/ml). Responses of normal skin 
fibroblasts  were varied,  and mean net receptor number was unchanged. Increases in PDGF c~ 
receptor number by TGF-B occurred consistently with SSc fibroblasts  and low concentrations 
of TGF-~/(0.1-1 ng/ml) were particularly stimulatory. Increased surface expression of ot receptor 
subunit by TGF-~ in SSc fibroblasts correlated with increased new PDGF ot receptor synthesis 
as demonstrated by radioimmunoprecipitation analysis of metabolically labeled cells and with 
increased steady-state levels of corresponding mRNAs. In normal adult skin fibroblasts, TGF-B 
had no effect on either synthesis or mRNA expression of c~ receptor subunits. Proliferative responses 
to PDGF-AA after pretreatment with TGF-B correlated positively with effects of TGF-~ on 
expression  of o~ receptor subunit. Decreased  mitogenic responses to PDGF-AA were observed 
in foreskin fibroblasts,  small changes in responses in adult fibroblasts,  and significant  increases 
in SSc fibroblasts. Thus, costimulation with PDGF-AA and TGF-B selectively  enhanced proliferation 
of fibroblasts  with the SSc phenotype. Immunohistochemical examination of SSc and control 
skin biopsies revealed the presence of PDGF-AA in SSc skin. Data obtained by ligand binding, 
immunoprecipitation, mRNA, and mitogenic techniques are consistent with the hypothesis that 
activation of the PDGF-AA ligand/ol receptor pathway is a characteristic  of the SSc fibroblast 
and may contribute to the expansion of fibroblasts  in SSc. 
S 
cleroderma (systemic sclerosis, SSc)  1 is a complex connec- 
tive tissue disease of unknown etiology, in which fibrosis 
develops in the skin and internal organs in association with 
vascular insufficiency. Scleroderma skin fibroblasts express a 
phenotype distinct from that of normal skin fibroblasts. Char- 
acteristics of this phenotype include: enhanced mRNA ex- 
pression of several extracellular matrix genes (collagens I, III, 
VI; fibronectin, proteoglycan), and an abnormality of cell 
growth that includes insensitivity to the induction of quies- 
cence by serum deprivation and persistent c-myc mRNA ex- 
pression (1, 2). Since the matrix characteristics  are recreated 
1 Abbreviations used in this paper: PDGF, platelet-derived growth factor; 
SFM, serum-free  medium; SSc, systemic sclerosis. 
in vitro by exposure of diploid fibroblasts to TGF-~/(3), we 
have studied the role of TGF-/~ in the cell growth regulation 
of SSc (4).  We report herein a significant  upregulation of 
platelet-derived growth factor (PDGF) oe receptors after TGF-/3 
exposure,  a phenomenon that is limited to SSc fibroblasts. 
PDGF, a major smooth muscle cell and fibroblast mitogen, 
exists as a dimer of two homologous polypeptide chains, A 
and B. Heterodimer (PDGF-AB)  and homodimer (PDGF- 
AA, PDGF-BB) isoforms have been purified from natural 
sources and are biologically active (5, 6). Human platelets 
contain PDGF-AB (40%),  PDGF-AA (30%),  and PDGF- 
BB (30%) (7). Two distinct PDGF receptor subunits, denoted 
o~ and/3, have been identified. The o~ receptor subunit binds 
all three isoforms of PDGF, whereas the B receptor subunit 
binds PDGF-BB with high affinity, PDGFoAB with lower 
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receptor subunits are structurally and functionally related and, 
together with c-kit product and CSF-1 receptor, belong to 
a subfamily of tyrosine kinase receptors (10).  Dimerization 
of receptor subunits is required for activation, and several sub- 
strates for activated receptor recently have been identified, 
including phosphoinositol (PI) kinase (11), phospholipase C-y 
(12,  13),  Raf-1 kinase (14),  and GAP protein  (15,  16).  In- 
terestingly,  there appear to be differences in the targets  of 
the  postreceptor  signals  transduced  by cx  and/3  receptor 
subunits (17, 18). Relative number and ratio ofc~ to/3 receptors 
vary in different cell types and correlate with mitogenic re- 
sponses to specific  PDGF isoforms (8).  In NIH-3T3  cells, 
where the number  of c~ and/3  receptors are similar,  both 
PDGF-AA  and  BB  stimulate  DNA  synthesis  with  equal 
potency. In nonimmortalized, nontransformed human fibro- 
blasts that predominantly express/3 subunits on the cell sur- 
face, higher constitutive mitogenic responses to PDGF-BB 
than  to PDGF-AA are usually observed. 
Recent studies indicate that selected growth factors have 
the capacity to modulate proliferative responses to PDGF iso- 
forms by affecting the expression of PDGF receptor subunits. 
For example, we have observed increased responses to all three 
PDGF isoforms implying increased receptor oL subunit ex- 
pression after pretreatment  of human  skin fibroblasts with 
TGF-/3 (19).  Increased proliferative responses to PDGF-AA 
and specific induction of PDGF o~ receptor subunit, but not 
/3 receptor subunit, were observed in osteoblast-enriched cul- 
tures in response to Ibl (20), and in vascular smooth muscle 
cells in response to basic fibroblast growth factor (FGF) (21). 
However, in smooth muscle cells,  foreskin fibroblasts, and 
chondrocytes, decreased synthesis of o~ receptor subunit after 
exposure to high concentrations  of TGF-/3 correlated with 
decreased proliferative effects of TGF-/3 (22). Similarly, TGF-/3 
decreased mitogenic responses to PDGF-AA in NIH-3T3 cells, 
an effect that correlated with decreased cx subunit number, 
while/3  subunits  were slightly increased  (23).  In general, 
PDGF o~ receptor expression is downregulated by TGF-/3 in 
cells  whose constitutive ol receptor expression is high and 
unregulated  in cells whose constitutive expression is low. 
Growth factors, such as PDGF isoforms, are expressed and 
considered to be important  during embryogenesis (24) and 
normal tissue remodelling (25). In addition, recent evidence 
links them to a number of proliferative diseases. Several studies 
have  indicated  the  presence  of PDGF-BB  and  PDGF  /3 
receptors in atherosclerotic plaques (26-28),  in pulmonary 
fibrosis (29, 30),'in synovium from rheumatoid arthritis (31, 
32), as well as in SSc (33, 34). These observations are consis- 
tent with a role for PDGF-BB ligand//3 receptor interaction 
in smooth muscle cell proliferation in diseases with vascular 
involvement. 
Because of the possible relevance to the process of fibrosis 
of our recent finding that TGF-fl increases responsiveness to 
PDGF isoforms in diploid dermal fibroblasts via upregula- 
tion of o~ receptor subunit (19), further investigation of this 
arm of the PDGF system was initiated. We present evidence 
herein  that  SSc fibroblasts exhibit distinct  upregulation  of 
ol receptor subunits by TGF-fl and increased responsiveness 
to PDGF-AA, as compared with healthy adult and newborn 
foreskin fibroblasts.  Such characteristics  of SSc fibroblasts may 
be important  for the in vivo expansion of these cells.  The 
identification  of PDGF-AA in scleroderma dermal biopsies 
supports  this hypothesis. 
Materials and Methods 
Cells.  Fibroblasts were obtained by skin biopsy from affected 
areas (dorsal forearm) of patients with diffuse cutaneous SSc with 
<2 yr of skin thickening. Control fibroblasts were obtained by bi- 
opsy of healthy donors (within several  days of SSc biopsy) matched 
with each SSc patient for age, race, sex, and biopsy site, and processed 
in parallel. Newborn foreskin fibroblasts were obtained from the 
delivery suites of affiliated hospitals. All biopsies were obtained with 
informed consent and institutional  approval. Primary explant cul- 
tures  were established in 25-cm  2 culture  flasks in DMEM sup- 
plemented with 10% FCS, 2 mM-glutamine,  and 50/~g/ml gen- 
tamicin. Amphotericin  (5/~g/ml)  was included for the first week 
only. Monolayer cultures were maintained  at 37~  in 5% CO2 
in air. Fibroblasts between the third and fifth subpassages were used 
for experiments.  Fetal fibroblast strains (GM-00011, GM-05386, 
GM-08447) and foreskin fibroblast strain AG0152 were obtained 
from the Mutant Cell Repository (Camden,  NJ). 
12sl PDGF Binding Assay.  Saturation  binding assays were done 
according to the method of Bowen-Pope and Ross (35). Cells (2 
x  104/well) were plated in 24-well trays in DMEM supplemented 
with 10% FCS, grown to confluence, and incubated for 24 h in 
DMEM with 0.1% BSA. Two wells from each plate were used for 
cell number determination  (mean  _+ SD  =  5.8  _+ 0.5  x  104 for 
SSc cells, 5.8  _+ 1.2  x  104 for normal cells, and 5.6  -+ 0.6  x  104 
for foreskin cells). CeUs were then incubated with various concen- 
trations of TGF-/8 (K&D Systems, Inc., Minneapolis, MN) for 8 h, 
which has previously been shown to be the optimal time for max- 
imal induction of PDGF a receptor (see reference 19). Control cells 
were incubated in DMEM/0.1% BSA (serum-free medium; SFM) 
during this time. Medium containing  TGF-B was removed, and 
varying concentrations  (0.125-8 ng/ml) of 12SI-labeled  PDGF-AA 
(sp act, 70 #Ci/#g; purchased from Upstate Biotechnology, Inc., 
Lake Placid, NY; custom iodinated by Biomedical  Technologies, Inc., 
Stoughton, MA) were added in binding buffer for 2 h at 4~  Cells 
were then washed with PBS/0.1% BSA, harvested with solubiliza- 
tion buffer, and total cell-associated ~2Sl was determined. Nonspec- 
ific binding was determined by addition of 100-fold excess of unla- 
baled PDGF-AA or PDGF-BB (UBI Inc.). Binding isotherms were 
analyzed as described by Scatchard (36), and receptor number was 
calculated according to the following formula:  receptor number 
=  (R1)(2  ￿  10 -4) (6.023  x  10z3)/cell number;  where R1  =  x 
intercept from Scatchard plot M/L; 2  x  10 -4 =  reaction volume 
in liters; 6.023  x  1023 =  Avogadro number. 
Statistics.  PDGF c~ receptor numbers for pairs of control and 
SSc fibroblasts were compared using Student's t test for paired vari- 
ables. Differences between foreskin and normal and SSc cells were 
analyzed using  the Student's  t test for unpaired variables. 
DNA Synthesis.  Cells were plated in 24-well trays in DMEM 
with 10% FCS and grown to confluence, followed by 24 h incuba- 
tion in DMEM with 0.1% BSA (SFM). Cells were then incubated 
with I ng/ml of TGF-fl (K&D Systems Inc.) for 8 h. Control cells 
received no TGF-fl. TGF-fl was washed off, and cells were stimu- 
lated with 10 ng/ml of PDGF-AA homodimer (UBI Inc.) for 24 h 
in the absence of serum or other growth factors. Cells were labeled 
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1/~Ci/ml; New England Nuclear, Boston, MA) for 2 h, washed 
three times with cold PBS, and four times with TCA. 500/~1 of 
0.1% NaOH/0.1% SDS was added and the radioactivity of  250-/zl 
aliquots was  measured in  5 ml of PCS  II (Amersham Corp., 
Arlington Heights, IL) using a liquid scintillation system (Packard, 
Sterling, VA). 
RNA Preparation  and Northern Blot Analysis.  Ceils  were grown 
to confluence in DME supplemented with 10% FCS in 15-cm- 
diameter dishes (Falcon  Labware,  Oxnard, CA), washed three times 
with SFM, followed by a 24-h preincubation in this medium. 
Medium was replaced with DME containing 1 ng/ml of TGF-B 
for 8 h.  Total RNA was extracted using an acid guanidinium 
thiocyanate-phenol-chloroform  method (37). 20 #g of total RNA 
was subjected to dectrophoresis on 1% agarose/formaldehyde  gd 
and blotted onto nylon falters (ICN Biochemicals, Inc., Cleveland, 
OH).  The filters were baked, prehybridized, and hybridized as 
follows. After a 2-h incubation at 42~  in prehybridization buffer 
(50% deionized  formamide, 5 x Denhardt's solution, 1% SDS, 5 x 
SSPE, and 100/xg/ml herring sperm DNA), filters were hybrid- 
ized overnight with 5  x  106 cpm/ml of labeled probe at 42~ 
in the same buffer, followed by two washes in 2 x  SSPE for 15 
min at room temperature, two washes in 2x  SSPE/2% SDS for 
45 min at 55~  and two washes in 0.1x  SSPE for 15 min at room 
temperature. Filters were exposed to Kodak X Omat AR film at 
-70~  for 5 d. The probes (1.6-kb BamI fragment from 3' non- 
coding region of  or receptor cDNA; generous  gift from S. Aaronson, 
National Institutes of Health and glyceraldehyde  3-phosphate de- 
hydrogenase) were labeled with a random primed DNA labeling 
kit (Boehringer Mannheim Biochemicals, Indianapolis, IN). 
Metabolic Labeling.  Fibroblasts were grown to near confluence 
in 10-cm  2 dishes in DME containing 10% FCS. The cells were 
washed three times with DME containing 0.1% BSA (SFM) and 
incubated with SFM for 1 h. The cells were then incubated with 
or without 1 ng/ml of TGF-~ ((;enzyme, Boston, MA) for 5 h, 
washed twice with methionine-free medium, and incubated for 20 
min at 37~  then labeled with 200 #Ci/ml of ~SS-methionine  in 
methionine-free medium for 3 h in  10%  CO2. After washing 
twice with ice-cold PBS, the cells were lysed with 1 ml of triple 
detergent lysis  buffer (0.5% sodium deoxycholate,  1% NP-40, 0.1% 
SDS, 1/~g/ml aprotinin, 100/~g/ml PMSF, 0.02% sodium azide, 
50 mM Tris-HC1, pH 8.0, 0.15 M NaC1) for 1 min at 4~  Chilled 
lysate was scraped and centrifuged at 12,000 g for 2 rain at 4~ 
The protein content and radioactivity of  each clarified  extract were 
determined using a protein assay and scintillation counting proce- 
dure (Bio-Rad Laboratories, Richmond,  CA). 
lmmunoprecipitation.  Labeled  extracts were precleared by incu- 
bation with normal mouse serum for 1 h at 4~  followed  by precipi- 
tation with killed, fixed Stap~lococcus aureus ceils (Cowan strain). 
After preclearance, the extracts were incubated with anti-PDGF 
c~ receptor antiserum or preimmune serum at 4~  for 1 h. The 
immunocomplexes  were absorbed by protein A-Sepharose. The gels 
were then washed twice with NET-gel  buffer (0.1% NF-40, 1 mM 
EDTA, 0.25%  gelatin, 0.02%  sodium azide, 50 mM Tris-HC1, 
pH 7.5, 150 mM NaC1) and once with 10 mM Tris-HC1, pH 7.5, 
0.1% NP-40. The final immunocomplexes were dissociated from 
the gels using 1% SDS and analyzed  by 4-15% gradient SDS-PAGE 
and autoradiography. 
Iraraunohistochemistry.  Frozen  sections  of skin biopsies from five 
SSc patients and five  healthy controls were investigated  for the pres- 
ence of PDGF-AA ligand using  polyclonal rabbit  anti-human 
PDGF-AA antiserum (Genzyme). Punch biopsies were frozen in 
OCT medium (Miles Laboratories, Naperville, IL) and stored at 
- 70~  Frozen sections (6-/~m thick) were fixed  by air drying and 
incubated with anti-PDGF-AA or preimmune rabbit IgG (1:40 di- 
lution in PBS) at 37~  for 1 h. AU sections were washed three 
times for 10 min with PBS, followed  by incubation  with biotinylated 
goat anti-rabbit IgG (R&D Systems)  for 30 min at 37~  Sections 
were then incubated with avidin-peroxidase  complex (Boehringer 
Mannheim Biochemicals) for 45  min and with substrate 3,3'- 
diaminobenzidine (Aldrich Chemical Co., Milwaukee, WI) and 
H20 for 15 min. Sections were counterstained with hematoxylin. 
Results 
Effect of TGF-~ on c~ Subunit Expression Is Cell Type Depen- 
dent.  To investigate the expression of PDGF cr subunits, we 
measured specific binding of t2SI-labded PDGF-AA (PDGF- 
AA binds with high affnity to PDGF oL receptor subunit 
and does not bind to ~  subunit). The effect of TGF-~/on 
the expression of PDGF c~ receptors was measured under ex- 
perimental conditions previously established  (19). In a typ- 
ical experiment, cells were grown to confluence in DME sup- 
plemented with 10% FCS then transferred for 24 h to SFM. 
Cells were then pretreated with TGF-~ (1 ng/ml) for 8 h 
(previously determined optimal time) followed by binding 
of several concentrations of z2SI-labded PDGF-AA (0.125-8 
ng/ml). Binding data were used for Scatchard  analyses and 
calculation of binding site affinity and prevalence.  Human 
fibroblasts  analyzed were of different origin: normal adult 
skin, SSc skin, fetal skin, and newborn foreskin. Cell strains 
used originated from biopsies  in our laboratory (except for 
fetal skin cell strains, obtained from Mutant Cell Repository, 
Camden, NJ) and were grown under identical conditions and 
examined only in early passage. A newborn foreskin cell line, 
AG01523,  used for measurements of PDGF receptors  (38), 
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Figure 1.  Effect  of TGF-~ on PDGF  ~ receptor  expression  in SSc, normal 
adult skin (NS), foreskin  (FS), and fetal  fibroblasts. Confluent,  quiescent 
cells were preincubated with TGF-B  (1.0 ng/ml) followed  by binding of 
several concentrations  (0.128-8 ng/ml) of 12sI PDGF-AA (see Materials 
and Methods). Data are presented as the ratio of receptor numbers per 
cell with TGF-B treatment  to receptor numbers per cell without TGF-~/ 
treatment. 
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AG01523  FS  NS1  NS2  NS3  SScl  SSc2  SSc3 
Rec  Rec  Rec  Rec  Rec  Rec  Rec  Rec 
TGFfl  no.  Kd  no.  Kd  no.  Kd  no.  Kd  no.  Ka  no.  Kd  no.  Kd  no.  Ka 
ng/ml  pM  pM  pM  pM  pM  ioM  pM  pM 
0  36,000  90  8,600  45  3,000  60  2,500  32  10,000  30  3,500  50  5,600  60  4,200  25 
0.1  14,000  50  4,500  9  2,000  20  1,200  31  9,000  50  4,000  60  8,700  80  -  - 
0.5  14,000  50  -  -  2,800  40  ....  5,400  80  -  -  4,300  25 
1  10,000  40  1,400  27  3,000  40  330  12  10,000  80  4,500  50  7,600  100  6,000  27 
These data  (1.0 ng) represent  a portion of the points of Fig.  1.  Experimental  conditions for all cells are the same as described for Fig.  1. 
FS, foreskin fibroblasts; NS,  normal adult  skin fibroblasts; SSc, scleroderma fibroblasts;  Rec  no., values represent  receptor  number per cell. 
was included as an internal control. Fig. 1 summarizes results 
obtained from five foreskin, three fetal cell strains,  and seven 
pairs  of SSc and matched healthy control skin fibroblasts. In 
all foreskin and fetal  fibroblasts cell strains  studied,  TGF-B 
pretreatment  decreased PDGF receptor c~ subunit  number. 
SSc fibroblast strains increased PDGF ol receptor number 1.6 
_  0.47 (mean  +_ SD) -fold after exposure to I ng/ml TGF-B, 
while normal adult fibroblasts showed no increase (0.92  + 
0.27) (p =  0.03). The SSc fibroblast response was very different 
from that of foreskin cells (0.61  _+ 0.25) (p  =  0.002). There 
was no statistical difference between the foreskin and normal 
adult  cell responses. 
Effect of TGF-~ on Expression of oe Subunit  Is Dose Depen- 
dent.  We previously established that  a dose of TGF-~ of 1 
ng/ml stimulates responses to PDGF maximally in skin fibro- 
blasts (19).  However, recent studies by Battegay et al.  (22) 
indicated that TGF-/3 may be active in lower concentrations. 
We therefore examined the effect of different doses of TGF-B 
(0.1-1 ng/ml)  on the expression of c~ subunits in three SSc 
and three adult skin ceU strains and two foreskin fibroblasts 
cell lines (AG 01523 and a foreskin cell line obtained in our 
laboratory). As shown in Table 1, the commercially available 
cell line AG 01523 exhibits significantly higher constitutive 
receptor  number compared with cell lines  obtained in  our 
laboratory. TGF-B inhibited expression of c~ subunit in both 
foreskin fibroblasts and in one adult skin fibroblast cell line 
in a dose-dependent manner. Two adult skin fibroblast strains 
were relatively insensitive to the inhibitory effects of TGF-B. 
All three scleroderma cell lines showed induction of PDGF 
o~ receptor expression between 0.1 and 1 ng/ml  of TGF-B. 
TGF-[3 Stimulates Synthesis Of PDGF ol Receptor Protein in 
SSc Fibroblasts.  To investigate the mechanism of TGF-~ in- 
duction ofo~ receptor surface expression, we examined whether 
TGF-B affects  synthesis of new receptor  subunits.  SSc and 
adult  skin  fibroblasts were metabolically labeled with  3sS- 
methionine  in the presence or absence of TGF-fl followed 
by immunoprecipitation  with anti-PDGF ol receptor mAb. 
As shown in Fig. 2, TGF-/3 increases  synthesis of c~ subunit 
in  SSc, while  no  effect  is  observed in  normal  adult  skin 
fibroblasts. 
TGF-t3 Modulates PDGF c~ Receptor mRNA Leve/s.  To fur- 
ther investigate the mechanism of TGF-B modulation of PDGF 
o~ receptor expression, we examined the effect of TGF-/5  on 
ol receptor message levels. RNA was extracted from confluent 
cells incubated in serum-free medium for 24 h followed by 
8 h  of incubation with or without  1 ng/ml  of TGF-/~.  As 
shown in Fig. 3, TGF-/5 directly influences mRNA levels of 
ot receptor subunit with different effects noted in the three 
cell  strains.  In  SSc  fibroblasts,  TGF-B  induces  c~  subunit 
mRNA expression levels but has no effect on message levels 
in adult skin fibroblasts.  In agreement with studies of Battegay 
et al. (22), TGF-r  decreases ot subunit mRNA levels in fore- 
skin  fibroblasts. 
Mitogenic Responses to PDGF-AA Correlate with PDGF oL 
Receptor Expression.  Parallel  to the receptor expression studies, 
we examined the effect of TGF-~ on the mitogenic respon- 
siveness of fibroblasts to PDGF-AA. Briefly, cells were grown 
to confluence, deprived of serum in SFM for 24 h, and then 
divided into four groups. One group of cells was pretreated 
with TGF-B (1 ng/ml) for 8 h, then stimulated with PDGF- 
Figure 2.  Radioimmunoprecipitation  of PDGF~ receptor subunits in 
SSc and adult skin fibroblasts. Cells were grown, stimulated with TGF-B, 
and metabolically labeled with  ssso4  as  described (see Materials  and 
Methods). Equal concentrations of protein from each labeled extract were 
immunoprecipitated  with anti-PDGF c~ receptor antibody and analyzed 
by 4-15% gradient SDS-PAGE and autoradiography. Three SSc cell lines 
and one representative normal adult skin (NS) cell line are depicted. (+) 
Stimulated with TGF-r  (-) unstimulated (1 ng/ml). 
1230  Upregulation of Platelet-derived Growth Factor c~ Receptor Figure 3.  Northern blot analysis of PDGF a  receptor mRNA in fore- 
skin (FS), SSc, and normal skin (NS) fibroblasts. RNA was extracted from 
confluent cells incubated for 8 h with TGF43 (1 ng/ml) (+) or DME/0.1% 
BSA  (-).  (~s  6.4-kb PDGF r  receptor  mRNA;  (bottom) GAPDH 
mRNA. 
AA for 24 h.  The second group was treated with TGF-~/ 
only for 32 h. The third group did not receive TGF-B;  in- 
stead,  SFM was added for 8 h, then PDGF-AA was added 
for 24 h. A fourth or control group received no growth factors; 
cells were maintained in SFM. After stimulation with growth 
factors,  [3H]thymidine was added to all cells for 2 h and in- 
corporation of [3H]thymidine into DNA was determined. 
As shown in Fig. 4, TGFq~ alone and PDGF-AA alone are 
weak mitogens with similar levels of responses  in all three 
cell types. However, after pretreatment with TGF-~, the mito- 
genic responses to PDGF-AA differ significantly between all 
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Figure 4.  Effects  of TGF-B preincubation on mitogenic responses to 
PDGF-AA in newborn foreskin (FS), adult skin (NS), and SSc fibroblasts. 
Confluent, quiescent cells in serum-free conditions were stimulated with 
TGF-B (1 ng/ml) alone, PDGF-AA (10 ng/ml) alone, or with pretreat- 
ment with TGF-B as described in the text. Values represent mean _+  SD 
from nine FS, five NS and six SSc cell lines, with each experiment  per- 
formed  in triplicate wells. 13H]Thymidine incorporation (cpm) in con- 
trol wells, which did not receive any growth factors, was set at 100%; 
values from growth factor stimulated cells represent percent increases over 
control. 
cell types and correlate with the effects of TGF-3 on expres- 
sion of ot receptors in each cell type. In foreskin fibroblasts, 
the mitogenic  response to PDGF-AA was abrogated by TGF-3 
pretreatment in all nine cell lines tested. In adult fibroblasts, 
responses were variable: one cell line showed enhancement 
of responses to PDGF-AA, in two cell lines TGF-3 pretreat- 
ment did not have any significant effects on response to PDGF- 
AA, and in two cell lines inhibition of responses  was  ob- 
served. In six SSc fibroblast  cell lines, TGF-3 pretreatment 
consistently enhanced responses to PDGF-AA. The relatively 
large variation in the magnitude of responses observed here 
is most likely due to heterogeneity of the fihroblast popula- 
tion (39),  a frequent finding in fibroblast  mass cultures de- 
rived from different donors. The mitogenic assay data are 
consistent with the data obtained by ligand binding, immu- 
noprecipitation, and mRNA analysis. 
Expression of  PDGF.AA in SSc Skin,  The present in vitro 
evidence, that SSc fibroblasts  from involved skin selectively 
respond to TGF-3 by upregulating PDGF-c~ receptors, thereby 
enhancing fibroblast proliferative capacity if PDGF-AA is avail- 
able, remains to be fully confirmed in vivo. Whereas TGF-3 
has been shown to be present in involved SSc skin in close 
proximity to fibroblasts  expressing type I collagen message 
(40, 41), we investigated whether PDGF-AA is also present 
in SSc lesions. We performed immunostaining  of SSc and con- 
trol skin biopsies with antiPDGF-AA-specific antibody. Con- 
trol skin biopsies showed little to no specific staining. In con- 
trast, all SSc biopsies stained positively, including hair follicles 
(suggesting synthesis of PDGF-AA by keratinocytes),  small 
capillaries (endothelial cell/pericyte), as well as selective  stromal 
cells. Fig. 5 is representative  of the staining observed in in- 
volved SSc skin biopsies  compared with control. Foreskin 
showed staining intermediate between that of adult control 
and SSc skin (data  not shown). 
Discussion 
In this study we demonstrate that fihroblasts from involved 
SSc skin, in contrast to healthy controls or newborn foreskin 
fibroblasts,  exhibit upregulation of expression of PDGF c~ 
receptors in response to TGF-~.  The present data confrm 
the work of others (22),  showing that, for foreskin strains, 
low TGF-B concentrations (0.1 ng/ml) lead to 50% decreases 
of PDGF o~ receptor number. Expression of PDGF ot receptors 
in normal adult skin fibroblasts is variable but essentially un- 
changed after TGF-~. Differences between SSc and normal 
adult skin fibroblasts exposed to TGF-~/with regard to sur- 
face expression of c~ receptors subunits calculated by Scatchard 
analysis are confirmed by radioimmunopredpitation analysis 
with anti PDGF cr receptor mAb. In addition, these differ- 
ences in TGF-~ modulation of ol receptor membrane expres- 
sion in these three cell types correlate with the effect of TGF-~ 
on c~ receptor subunit mRNA levels. In foreskin fibroblasts, 
there is inhibition of c~ receptor mRNA expression by TGF-B; 
small and variable changes in expression are observed in healthy 
adult fibroblasts;  and in SSc fibroblasts,  ot receptor mRNA 
is substantially increased after TGFtS. Levels of c~ receptor 
expression correlated positively with mitogenic responses to 
1231  Yamakage  et al. Figure 5.  Immunohistochemical  evidence  for PDGF-AA  in scleroderma  skin. Frozen  sections  of skin  biopsy  of scleroderma  patient (right) and healthy 
control (left) were stained for the presence  of PDGF-AA ligand using polyclonal  rabbit anti-human PDGF-AA antiserum as described  in Materials 
and Methods.  Sections  of scleroderma  and normal  skin  incubated  with nonimmune  rabbit sermn  as a control  did not show  detectable  staining  (data  not shown). 
exogenous PDGF-AA. After pretreatment with TGF-B, fore- 
skin fibrobhsts showed decreased response to PDGF-AA, while 
SSc fibroblasts  showed substantial increases. 
Constitutively increased synthesis of extracellular matrix 
associated with increased expression of extracellular matrix 
genes is well documented in SSc fibroblasts  (1). Our previous 
studies have indicated proliferation abnormalities of those cells 
manifested as persistent expression of c-myc protooncogene 
and increased proliferation in low serum concentration (2). 
Results from the present study (upregulation of PDGF o~ 
receptor and increased proliferative responses to PDGF-AA) 
add new characteristics to the SSc fibroblast phenotype, ex- 
tend the range of growth abnormalities of SSc cells, and sug- 
gest mechanisms for selective proliferative advantages in vivo. 
For example, if present in vivo in the vicinity of fibroblasts, 
PDGF-AA and TGF-3 may provide a selective stimulus for 
expansion of fibroblasts with the SSc-like phenotype. Unlike 
PDGF-BB, which binds equally to oL and B receptors, PDGF- 
AA uses only c~ receptor for postreceptor signalling (8). We 
therefore examined whether PDGF-AA is present in SSc skin; 
detection of TGF-~ and PDGF-BB ligand has been previously 
described in SSc (33, 40, 41).  We found that while PDGF- 
AA is essentially absent in healthy skin, it is consistently found 
in SSc dermis localized around capillaries in the interstitium 
and around the hair follides. 
The sources of these cytokines in lesional SSc dermis are 
unknown. The vascular lesion in systemic sclerosis is mani- 
fested clinically as Raynand phenomenon and hypertensive 
renal crisis accompanied by platelet activation (42).  Platelets 
contain both PDGF-AA and TGF-B in granules and their 
release into lesions as a result of the vascular damage is likely. 
Also, mononuclear cell infiltrates present in SSc dermis con- 
tain macrophages and T cells (43).  Macrophages are capable 
of secreting both TGF-~ and PDGF-AA (29, 44) and activated 
T  cells are known to release TGF-~ (45).  Fibroblasts them- 
selves are capable of releasing TGF-~ and PDGF-AA (46, 47). 
Thus, ample sources of these cytokines exist in SSc dermis, 
and their combined effect on proliferation of fibroblasts with 
the SSc phenotype (high matrix production) may help to ex- 
plain the characteristic fibrotic lesions. 
1232  Upregulation  of Platelet-derived  Growth Factor ot Receptor At  present,  mechanisms  of  fibrosis  in  SSc  and  other 
fibroproliferative diseases are poorly understood. Factors such 
as PDGF and TGF-B, which are consistently found in fibrotic 
lesions, may directly stimulate fibroblasts to proliferate and 
synthesize extracellular matrix. Data presented in this study 
strengthen the hypothesis that fibroblasts are not simply passive 
components of fibrotic responses. Characteristics  of sdero- 
derma fibroblasts such as increased matrix synthesis and ab- 
normal proliferation probably play a role in the development 
of fibrosis; presently, however, the origin of these abnormal 
fibroblasts in the lesion is unknown.  One possibility is that 
normal fibroblasts, due to exposure to TGF-fl and/or other 
cytokines, become permanently activated. Alternatively, ex- 
pansion of a subpopulation of fibroblasts constitutively ex- 
pressing increased matrix genes may occur due to their en- 
hanced proliferative responsiveness to growth factors present 
in the lesion (PDGF A/c~ system). The heterogenous responses 
of healthy adult fibroblasts observed in our study favor the 
second alternative. A complete hypothesis concerning mech- 
anisms of fibrosis in SSc must include vascular/microvascular 
injury and helper T  cell activation, discussed elsewhere (1). 
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